BMJ Open Analysis and comparison of clinical practice guidelines regarding treatment recommendations for chronic tinnitus in adults: a systematic review

Sebastiaan Meijers (1), 1,2 Inge Stegeman (1), 1,2 Josephine A van der Leun, 1 Saloua A Assegaf, 1 Adriana L Smit 1,2

To cite: Meijers S, Stegeman I, van der Leun JA. et al. Analysis and comparison of clinical practice guidelines regarding treatment recommendations for chronic tinnitus in adults: a systematic review. BMJ Open 2023;13:e072754. doi:10.1136/ bmjopen-2023-072754

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2023-072754).

Received 21 February 2023 Accepted 25 August 2023



@ Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by

¹Otolaryngology and Head and Neck Surgery, UMC, Utrecht, Netherlands ²UMC Utrecht Brain Center, Utrecht, Netherlands

Correspondence to

Dr Adriana L Smit; A.L.Smit-9@umcutrecht.nl

ABSTRACT

Objectives To determine if, and to what extent, published clinical practice guidelines for the treatment of chronic tinnitus vary in their recommendations.

Design Systematic review of guidelines.

Data sources PubMed, EMBASE and GIN electronic databases were searched in March 2022 and the search was updated in June 2023.

Eligibility criteria We included clinical practice guidelines that gave recommendations on the treatment of tinnitus. No language restrictions were applied.

Data extraction and synthesis Two independent reviewers extracted the data and used the AGREE checklist to report on reporting.

Results A total of 10 guidelines were identified and included, published between 2011 and 2021. Recommendations for 13 types of tinnitus treatments were compared. Large differences in guideline development and methodology were found. Seven of the 10 guidelines included a systematic search of the literature to identify the available evidence. Six of the 10 guidelines used a framework for the development of the guideline. Reporting was poor in multiple guidelines. Counselling and cognitive behavioural therapy were the only treatments that were recommended for treating tinnitus associated distress by all guidelines that reported on these topics. Tinnitus retraining therapy, sound therapy, hearing aids and cochlear implantation were not unanimously recommended either due to the lack of evidence, a high risk of bias or judgement of no beneficial effect of the specific treatment.

Conclusions There were notable differences with respect to whether guidelines considered the available evidence sufficient enough to make a recommendation. Notably, we identified substantial differences in the rigour of guideline design and development. Reporting was poor in many guidelines. Future guidelines could benefit from the use of reporting tools to improve reporting and transparency and the inclusion of guideline experts and patients to improve the quality of clinical practice guidelines on tinnitus.

INTRODUCTION

Chronic tinnitus is a heterogeneous condition with a high variety of symptoms and wide diversity in tinnitus related impact on daily

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ In-depth evaluation and comparison of the recommendations for treatment of tinnitus by different auidelines.
- ⇒ Designs of different tinnitus guidelines were compared in a systematic way.
- ⇒ There was no published research protocol for this study.

life. In clinical practice, tinnitus patients do present with different needs to a wide range of different healthcare providers. Depending on the country, institute or healthcare setting at which patients present with their tinnitus, treatment pathways vary¹² A high-quality and up-to-date clinical practice guideline could aid these physicians to provide evidence based advise for the diagnosis and treatment of tinnitus.

Clinical practice guidelines are defined as: 'Statements that include recommendations, intended to optimise patient care, that are informed by systematic review (SR) of evidence and an assessment of the benefits and harms of alternative options'. Nowadays, clinical practice guidelines are considered to be an evident consequence of evidence-based medicine and facilitate physicians and healthcare workers to incorporate the best available evidence in daily practice. 45

The number of clinical guidelines has increased dramatically over the past decade. As a consequence, several guidelines can exist on the same topic, often within the same geographic region. Those guidelines may vary in their recommendations and in the provided strength of recommendation, especially when the available evidence is weak. ⁶⁷ Factors that may contribute to disparities between clinical practice guidelines are the lack of high-quality evidence, differences



9

in the interpretation of the evidence, different methods to establish the guideline, socioeconomic differences, cultural influences regarding expectations of risks and benefits and differences in healthcare systems.8 Whether the available evidence is considered to be of low or high quality, all recommendations that are given in clinical practice guidelines require both evaluation of the evidence and consensus from the development team regarding the interpretation of the evidence and the possible harm versus benefit of the recommended intervention. Comparing recommendations between guidelines on the same topic, its development and the level of evidence stated for each recommendation could help physicians to unravel the reason for discrepancies and guide their decision or judgement on how to handle the content of a guideline. Also, it could initiate a debate about how to improve the development and application of guidelines in clinical care such as tinnitus treatments, which is fuelled by the recent opinion paper by Langguth et al on the strength and pitfalls of tinnitus guidelines.1

Therefore, we aim to determine the differences in recommendations between clinical practice guidelines that report on the treatment of chronic tinnitus. We assess the differences in design and execution of guideline development, content of the recommendations and the provided level of evidence to identify similarities and discrepancies.

METHODS

Search strategy and selection of tinnitus guidelines

We conducted a systematic literature search on the 2 March 2022, which was updated the 20 June 2023 in the PubMed, EMBASE and GIN digital literature databases to identify clinical practice guidelines regarding the treatment of chronic tinnitus in adults (see online supplemental file 1 for the search strategy). No restrictions regarding publication date or language were applied. Articles were eligible for inclusion if in the publication the authors stated to develop or regarded their work as being a clinical practice guideline. Guidelines for children, evidence reports without recommendations or comments on existing guidelines were excluded. The search results were screened on title and abstract after removal of duplicates using predefined inclusion and exclusion criteria that are mentioned before by two researchers independently (SM and IS). Rayyan software was used. 10 The selected articles were read in full by two researchers (SM, IS or AS). Reference lists of the included articles were reviewed to select relevant articles which were not identified in the search. Disagreement between researchers was resolved by discussion till consensus was reached. This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.11

Data extraction

Data regarding country of origin, year of publication, included treatment options, professionals and organisations which were involved within the guideline development, methods that were used to improve reporting of the guideline, methods used for classification of the level of evidence, methods used to grade the level of confidence in the evidence, methods used to grade the level of recommendation and the given recommendations were extracted from the guidelines. The search date of the literature study, the used digital databases, articles on which the evidence was based, study design of these articles, the preferred outcome measures to describe the treatment effect, the argumentation behind the recommendations, the intended target users and goals or aims of the guideline writers were also extracted. The data were extracted by two researchers independently (SM, IS or AS).

Assessment of reporting of the guidelines

The AGREE checklist instrument was used to evaluate the reporting in the included guidelines. ¹² Two authors (SM, IS or AS) independently filled out the checklist for each guideline. The AGREE checklist consists of 23 items which are divided into 6 domains: scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability and editorial independence. All items have multiple reporting criteria to evaluate and give an indication about the rigour of reporting in the guideline. We chose the AGREE checklist because it does not require to determine a score for each item, which makes outcomes less dependent on the personal opinion of the assessors.

Comparison of evidence and recommendations

We compared the recommendations for tinnitus treatments that were made in the guidelines based on the strength of the recommendation, level of evidence and the direction of the recommendation. Treatment options were included for comparison if two or more guidelines reported on the specific treatment option. The outcome measures that the guidelines intended to report and the actual reported outcomes for the recommendations on tinnitus treatments were also compared.

Analysis

The results of the data extraction were summarised with descriptive statistics. No quantitative analyses were performed because this was out of the scope of this review.

Patients and public involvement

None.

RESULTS

Search and selection

After removal of duplicates 468 articles were screened for eligibility on title and abstract. A total of 20 articles were read full text (figure 1). Four guidelines were identified through cross-referencing. Nine guidelines and one




Figure 1 Flow chart. Adopted from Page et al. 11

updated guideline were included in the analyses. The guidelines were published from 2011 to 2021. The guidelines were published in Denmark, Sweden, Japan, the Netherlands, Germany, the United Kingdom, Europe, Switzerland and the USA and were written in English, German, Danish, Swedish and Dutch. ^{13–22} The German guideline of 2015 was revised in 2021 and both were included. ¹⁴ ¹⁵

Goals of the guidelines

All guidelines reported their main goal. ^{13–21} In 3 out of 10 guidelines, they aimed to create more uniformity in the treatment of tinnitus patients. ^{13 17 19} In 4 out of 10 guidelines, they aimed to illustrate the available therapy options. ^{14 15 20 22} In 2 out of 10 guidelines, they aimed to provide evidence-based recommendations; ^{16 18} and in 1 guideline, they aimed to improve care for tinnitus patients. ²¹

Target users of the guidelines

The targeted users for the guidelines were clinicians managing patients with tinnitus, ^{14–16} ¹⁹ otolaryngologists, ¹³ ¹⁷ ²¹ audiologists ¹⁸ ²¹ and the staff of a hearing and balance clinic. ²¹ The guidelines were also addressed to: psychiatrists, ^{13–15} ¹⁹ general practitioners, ^{13–15} ²¹ psychologists, ^{13–15} ¹⁹ oral and maxillofacial surgeons, ¹⁵ neurologists, ¹⁵ dentists, ¹⁵ nurses, ¹⁹ social care workers, ²⁰ patients or patient organisations. ²⁰ ²¹

Reporting of the guidelines

In the scope and purpose domain, all guidelines were found to report their objectives except the Swiss guideline. Research questions and target populations were not always reported clearly. Stakeholder involvement domain: group membership was not clearly reported in the Japanese guideline where in other guidelines this was more clearly stated. Preferences and views of the

target population were not reported in 4 out of 10 guidelines. 16 18 19 21 Target users were reported in all guidelines. Rigour of development domain: In the Swedish, Swiss and Danish guidelines, there was no description of any systematic search of the evidence, external review or updating procedure. 18 21 22 Recommendation development was also not clearly reported in the Japanese and EÛ guideline. 1719 Clarity of presentation domain: key recommendations were not mentioned in 3 out of 10 guidelines. 18 21 22 Applicability domain: monitoring and auditing criteria and were not reported in any guideline. Resource implications were only reported in the UK guideline.²⁰ Editorial independence domain: the funding body was not reported in 3 out of 10 guidelines. 18 21 22 In 5 out of 10 guidelines, funding was not clearly reported. 13 14 16 17 19 Competing interests were not mentioned in two 2 of 10 guidelines. 18 21 See online supplemental file 2 for the AGREE checklist.

Guideline characteristics

Otolaryngological societies were responsible for the development of 5 (including one updated guideline) out of 10 guidelines. 13-17 The other guidelines were developed by national institutes of health, ^{18 20} a consortium, ¹⁹ a medical association²² or where hospital initiated.²¹ Otolaryngologists, (N=8) audiologists (N=6), psychologists and psychiatrists (N=6) were most frequently involved in the development. Eight out of 10 guidelines 13-1618-21 included multiple specialties in the development of their guideline, 1 out of 10 guidelines included only otorhinolaryngologists. ¹⁷ None of the guidelines reported the involvement of a methodologist/epidemiologist. Three guidelines reported the help of either information specialists or knowledge institutes. ¹³ 16 20 The USA guideline ¹⁶ and the UK guideline²⁰ reported that an information specialist assisted with the literature search. The Dutch guideline ¹³ reported that they had support from the Dutch Knowledge institute for medical specialists. See table 1 for summary characteristics of the included guidelines.

Guideline design: electronic literature databases used for evidence synthesis

Seven out of 10 guidelines reported the use of one or more electronic literature database (s) which they used for their evidence synthesis. $^{13-17}$ 19 20 In 6 out of the 10 guidelines, the Cochrane digital database was used. $^{13-17}$ 20 Four out of 10 used Medline 13 16 19 20 or/and PubMed, 14 15 17 19 EMBASE was used in 3 out of 10. 13 16 20 CINAHL was used in 3 out of 10. 16 19 20 Other used databases were the medical journal web, Guideline.gov, GIN and the google search engine.

Guideline design: outcome measures to evaluate tinnitus treatments

Eight out of 10 included guidelines reported the outcome on which they aimed to base their recommendation. ^{13–15} Tinnitus severity was mentioned in 8 out of 10 guidelines. ^{13–15} Tinnitus-related quality of life

in 3 out of 10, 13 17 19 possible harms of treatment in 1^{13} and general quality of life in none. In the final evidence synthesis, tinnitus severity was an outcome in 7 out of 10, $^{13-17}$ 19 20 tinnitus-related quality of life in 5 out of 10, 13 $^{15-16}$ 20 general quality of life in 5 out of 10^{13} 15 16 19 and possible harm of treatment in 4 out of 10.

Guideline design: reporting tools and checklists for guideline development

Six out of 10 guidelines used a tool or framework for their guideline development. Two guidelines 16 17 used the proposal for standardised reporting of clinical practice guidelines (COGS checklist). The USA guideline also used a clinical practice guideline development manual beside COGS. The German guideline and its update 14 15 both used the German Instrument for Methodological guideline appraisal (DELBI). The UK guideline 19 used the National institute for health and care excellence guideline framework and the Dutch guideline 13 used the report of the Dutch advisory commission for guidelines. The UK guidelines 15 used the report of the Dutch advisory commission for guidelines.

In 2 out of 10 guidelines, the Oxford Center of Evidence-Based Medicine criteria (CEBMC)²⁷ were used to grade the level of recommendation.¹⁵ In the 2021 revision of the German guideline, 14 both the CEBMC and the Grading of Recommendations, Assessment, Development and Evolutions framework (GRADE)²⁸ were used. In 2 out of 10 guidelines, GRADE was used to classify the level of evidence but in both guidelines no grading of the level of recommendation was provided. 13 20 In the American guideline, the recommendation classification of the American Academy of Pediatrics²⁹ was used to classify the level of evidence and CEBMC to grade the level of recommendation.¹⁶ In the Japanese guideline,¹⁷ the Minds manual V.2.0³⁰ was used to classify the level of evidence and the level of recommendation. Two guidelines did not use or did not report a classification system to grade the level of evidence or level of recommendation. 1821 Because none of the included guidelines used a similar combination of classification tools we were unable to compare the reported levels of evidence between guidelines. See table 2 for a summary of classification systems used in the guidelines.

Guideline design: included study designs for evidence synthesis

Seven out of 10 guidelines reported the aimed study design to include for evidence syntheses. ^{13–17} ¹⁹ ²⁰ Of these, 3 out of 10 aimed to include SR, meta-analysis (MA), randomised controlled trials (RCT)s or observational studies on tinnitus treatment. ¹⁴ ¹⁶ ¹⁹ In the German guideline and its update, they stated to include SR or RCTs when these were available or otherwise other study designs. ¹⁴ ¹⁵ In the Dutch guideline only treatment options for which an SR or MA was available were investigated. ¹³ In the European guideline, no specification was made on study designs to be included for evidence synthesis. Three guidelines did not report about the study designs to be



| Country of origin | Title | Year of publication | Included treatments | Professions involved in guideline development | Organisation responsible for guideline development |
|----------------------------------|---|---------------------|---|--|---|
| Sweden ²¹ | Tinnitus Vårdprogram (tinnitus care programme) | 2011 | Hearing aids, sound therapy, TRT | Audiologists, otorhinolaryngologists | Hearing and Balance Clinic Karolinska University Hospital |
| USA ¹⁶ | Clinical Practice Guideline: Tinnitus | 2014 | rTMS, CBT, Hearing aids, sound therapy, medication, dietary supplements, acupuncture, education and counselling. | Otorhinolaryngologist (paediatric and adult), neurotologist/otologist, neurologist, behavioural neuroscientist, geriatrician, audiologist, family physician, radiologist, physician, radiologist, psychiatrist, internist, psychoaucoustician, advanced nurse practitioner, resident physician and advocates, information specialist | American Academy of Otolaryngology-Head and Neck Surgery Foundation |
| Germany 2015 ¹⁵ | S3-Leitlinie Chronischer Tinnitus (Guideline chronic tinnitus) | 2015 | rTMS, TDCS, CBT, hearing aids, noise generators, hearing therapy, music therapy, acoustic neuromodulation, cochlear implantation, TRT, medication, dietary supplements, acupuncture, counselling, hyperbaric oxygen therapy. | Otorhinolaryngologist, audiologists, neurologists, psychiatrist, psychologists, paediatricians, dentists and patient representative groups | German society of otolaryngology and Head and Neck surgery |
| The Netherlands ¹³ | Richtlijn Tinnitus (Guideline tinnitus) | 2016 | TDCS, rTMS, CBT, Hearing aids, sound therapy, chochlear implantation, TRT, CR neuromodulation, alternative therapies. | Otorhinolaryngologist, clinical physicists, psychologist, behavioural therapists and patient representative groups. | Dutch society of otorhinolaryngology and Head and Neck surgery |
| Denmark ¹⁸ | Tinnitus-hyperacusis Vejledning I udredning og intervention (Tinnitus-hyperacusis Guidance in assessment and intervention) | 2017 | TRT, CBT, sound therapy, sleep advices. | Audiologist, hearing consultant | Danish Speech-Hearing- Vision Institutions |
| Europe ¹⁹ | A multidisciplinary European guideline for tinnitus: diagnostics, assessment and treatment | 2019 | rTMS, TDCS, tASC, Vagus nerve stimulation, CBT, hearing aids, sound therapy (masking therapy, neuromonics approach, notched music stimulation, costomised music stimulation), acoustic CR, cochlear implantation, TRT, medication, dietary supplements, acupuncture, invasive neurostimulators (beside cochlear implants) | Otorhinolaryngologist, neuroscientists, psychologist | TINNET consortium |

Continued

| Country of origin | Title | Year of publication | Included treatments | Professions involved in guideline development | Organisation responsible for guideline development |
|----------------------------|---|---------------------|---|---|--|
| Switzerland ²² | Guideline Tinnitus | 2019 | CBT, hearing aids, sound therapy, TRT, biofeedback and stress reduction program. Acupuncture, medication, vitamins, hyperbaric oxygen therapy, music therapy | Otorhinolaryngologist, internal medicine, medical doctor. | MEDIX (regional medical consortium) |
| Japan ¹⁷ | Clinical practice guidelines for diagnosis and treatment of chronic Tinnitus in Japan | 2020 | rTMS, CBT, Hearing aids, sound therapy, cochlear implantation, TRT, medication, acupuncture, laser therapy, counselling. | Otorhinolaryngologist | Oto-Rhino-Laryngological Society of Japan |
| UK ²⁰ | Tinnitus: assessment and management | 2020 | TDCS, acoustic CR neurostimulation, rTMS, CBT, mindfulness, hearing aids, sound therapy, medication (betahistamine), counselling. | Dean of health sciences school, consultant audiovestibular physician, head of audiology, advanced audiologist/ hearing therapist, general practitioner, clinical scientist, consultant clinical psychologist, clinical psychologist, consultant ENT surgeon, lay member, teacher of the deaf and consultant clinical scientist in audiology, information specialist | National Institute for Health and Care Excellence |
| Germany 2021 ¹⁴ | S3-Leitlinie Chronischer Tinnitus (guideline chronic tinnitus) | 2021 (update) | Counseling, hearing aids, noise generators, cochlear implants, hearing therapy, CBT, TRT, sound therapy, music therapy, medication, rTMS, TDCS, transcutaneous neurostimulation, low level laser, dietary supplements acupuncture, self-help. | Otorhinolaryngologist, psychiatrist, audiologist, dentist, behaviour therapist, psychologist, paediatrician, neurologist, patient representative groups, European tinnitus network* | German Society of Otolaryngology and Head and Neck Surgery |

*For the complete list of professionals involved see page 2: 017-064m_S3_Chronischer_Tinnitus_2021–2009_1.pdf (awmf.org). CBT, cognitive–behavioural therapy; CR, coordinated reset; NR, not reported; rTMS, repetitive transcranial magnetic stimulation; TDCS, transcranial direct current stimulation; TRT, tinnitus retraining therapy.

included for their synthesis or the evidence to support their recommendations. ¹⁸ ²¹ ²² See table 3 for a summary of the guideline design characteristics.

Tinnitus treatments included in guidelines

On the following tinnitus treatments guidelines reported a recommendation: counselling/tinnitus support (n=5), cognitive-behavioural therapy (CBT) (n=8), tinnitus retraining therapy (TRT) (n=8), sound therapy (n=6), hearing aids (n=8), cochlear implants (CI) (n=5), nervus vagus stimulation (NVS) (n=3), repetitive transcranial magnetic stimulation (rTMS) (n=7), transcranial direct current stimulation (TDCS) (n=5), acoustic coordinated reset (CR) neuromodulation (n=4), drug therapy (n=7), dietary supplements (n=4) and acupuncture (n=6).

Therapies were only evaluated when they were reported in two or more guidelines. Therefore, the recommendations on hyperbaric oxygen therapy, sleep advice, laser therapy, neuromonics approach and mindfulness were excluded from further analysis. For further information, see online supplemental files 3–7 and online supplemental file 8 (overview of recommendations).

Recommendations for tinnitus treatment

Counseling/CBT

Counselling was recommended with the same level of recommendation in 5 out of 10 guidelines that reported on this topic. ^{14–17 20} CBT was recommended in 8 out of 10 guidelines which reported on the topic with a minimal



Table 2 Summary of classification systems of level of evidence and grading systems of recommendation used in included clinical practice guidelines on the treatment of tinnitus

| Classification for level of evidence (used grading system) | | | Classification for grade of recommendation (used grading system) | | |
|--|---|--|--|---|--|
| Dutch guideline ¹³ | | | | | |
| (GRADE)‡ | | | (None) | | |
| High | | Very confident in the effect estimate. Further research is very unlikely to change confidence in estimate of effect | None reported | | |
| Moderate | | Moderately confident in the effect estimate. Further research is likely to have an important impact on our confidence in the estimate of the effect and my change the estimate | | | |
| Low | | Limited confident in the effect estimate. Further research is very likely to have an important impact on the confidence in the estimate of the effect and is likely change the estimate | | | |
| Very low | | Little confidence in the effect estimate. Any estimate of the effect is very uncertain | | | |
| European guideline ¹⁹ | | | | | |
| (CEBMC)§ | | | (GRADE) | | |
| 1a | | SR or RCTs | Strong recommendation | Level 1a, 1b or 2a evidence | |
| 1b | | Individual RCTs | | | |
| 1c | | All or none effects | | | |
| 2a | | SR (with homogeneity) of cohort studies | | | |
| 2b | | Individual cohort study | Weak recommendation | Level 2b, 2c or 3a evidence | |
| 2c | | 'Outcomes' research; ecological studies | | | |
| 3a | | SR (with homogeneity) of case- control studies | | | |
| 3b | | Individual case-control study | No recommendation | Only level 3b, 4 or five | |
| | 4 | Case series | | evidence | |
| | 5 | Expert opinion without explicit critical appraisal | | | |
| American guideline ¹⁶ | | | | | |
| (AAP, CEBMC)* | | | (AAP, CEBMC)¶* | | |
| Α | | Well-designed RCTs | Strong recommendation | Benefits clearly exceed the harms, grade A or B evidence quality | |
| В | | RCT; overwhelmingly consistent evidence from observational studies | Recommendation | Benefits exceed the harms, grade B or C evidence | |
| С | | Observational studies | Option | Evidence shows little clear advantage for approach, grade A, B or C | |

Continued

| Classification for lever system) | el of evidence (used grading | Classification for grade of reco system) | mmendation (used grading |
|----------------------------------|--|--|--|
| X | Exceptional situations where validating studies cannot be performed and there is a clear preponderance of benefits over harm | No recommendation | Unclear balance between benefits and harm and lack of pertinent evidence |
| Japanese guideline ¹⁷ | | | |
| (MINDS manual)** | | (MINDS manual)** | |
| A | Strongly confident in effect estimates | 1 | Strongly recommended |
| В | Medium confidence in the estimated effect | 2 | Recommended |
| С | Confidence in effect estimates is limited | | |
| D | The effect estimate is almost uncertain | | |
| UK guideline ²⁰ | | | |
| (GRADE)‡ | | (None) | |
| High | Further research is very unlikely to change our confidence in the estimate of effect | No explicit grading of the level of | recommendation |
| Moderate | Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate | | |
| Low | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate | | |
| Very low | Any estimate of effect is very uncertain | | |
| German guideline 201 | 5 ¹⁵ | | |
| (CEBMC)§ | | (CEBMC)§ | |
| High | SR (meta-analysis) or RCT or cohort studies of high quality | Strong recommendation | High evidence strength of effectiveness |
| Moderate | RCT or cohort studies of a lower quality | Recommendation | Moderate evidence strength of effectiveness |
| Weak | RCT or cohort studies of poor quality, all other study designs, expert opinion | Open recommendation | Weak evidence strength of effectiveness |
| None | No or negative results | No recommendation | |
| German guideline 202 | 1 ¹⁴ | | |
| (CEBMC)§ | | (AWMF)††† | |
| High | SR (meta-analysis) or RCT(s) or cohort study of high quality | Strong recommendation | High evidence strength of effectiveness |
| Moderate | RCT or cohort study of limited quality | recommendation | Moderate evidence strength of effectiveness |
| Weak | RCT or cohort study of bad quality, all other study designs, experimental studies. | Open recommendation | Weak evidence strength of effectiveness |



| Tal | hle | 2 | Con | tini | 10 |
|-----|-----|---|-----|------|----|
| | | | | | |

| Classification for level of evidence (used grading system) | | Classification for grade of recommendation (used grading system) | | |
|--|--|--|------|--|
| None | Negative outcomes or no outcome | No recommendation | None | |
| 1a | SR or RCTs | | | |
| 1b | Individual RCTs | | | |
| 1c | All or none effects | | | |
| 2a | SR (with homogeneity) of cohort studies | | | |
| 2b | Individual cohort study | | | |
| Danish guideline ¹⁸ | | | | |
| No classification s | ystem or grading system used or reported | d | | |
| Swedish Guideline | 21 | | | |
| No classification s | ystem or grading system used or reported | d | | |
| Swiss guideline ²² | | | | |
| No classification s | ystem or grading system used or reported | d | | |

[‡]Based on GRADE method.²⁸

difference in level of recommendation (from 'recommendation' to 'strong recommendation'). ^{13–17} ^{19–21}

Tinnitus retraining therapy

Eight out of the guidelines reported on TRT. ^{13–15} ^{17–21} The recommendation for TRT varied by guideline. In 2 out of 10 guidelines, TRT was recommended. ¹⁷ ¹⁸ In 3 out of 10, an open recommendation/option was given. ¹³ ¹⁴ ²¹ The reason for these open recommendations was that the variety in types of TRT was too high to come to an evidence-based recommendation. In 3 out of 10, it was stated that no recommendation could be made because of the limited quantity of SRs or RCTs on this topic ¹⁹ ²⁰ or the limited evidence for the effectiveness of TRT. ¹⁵

Sound therapy

In 7 out of 10 guidelines, information about sound therapy was provided. ¹³⁻¹⁶ ¹⁹⁻²¹ In 5 out of 10 guidelines, no recommendation was made because of the lack of evidence ¹³⁻²⁰ or by the risk of bias of outcomes for its effectiveness. ¹⁴⁻¹⁵⁻¹⁹ In the UK guideline, the authors did not make a clinical recommendation but stated that more research was needed before conclusions could be made on the effectiveness of sound therapy on tinnitus. ²⁰ In the USA guideline, sound therapy was recommended as 'an option'. They stated that, even though there is a lack of evidence, sound therapy is 'possibly effective in some cases'. ¹⁶ In the Swedish guideline, sound therapy

was also regarded as an option but there was no statement included on the evidence on which they based their recommendation.²¹

Hearing aids

Eight out of 10 guidelines reported on hearing aids. ^{13–17 19–21} In 5 out of 10 guidelines, ^{14 16 17 19 20} recommendations were made for the use of hearing aids in tinnitus patients with hearing loss, even though 3 guidelines out of these made this recommendation despite the lack of evidence on its effectiveness. ^{14 17 20} In the German guideline of 2015, ¹⁵ the authors did not recommend hearing aids substantiated by the lack of evidence for the effectiveness of hearing aids in normal hearing tinnitus patients. In the Dutch guideline, ¹³ a hearing aid was stated as being an option but without a clarification on which evidence this recommendation was based.

Cochlear implantation

Five out of 10 included guidelines reported on CI. ^{13–15} ¹⁷ ¹⁹ CIs were recommended in the Japanese guideline ¹⁷ and the German 2021 guideline, ¹⁴ in which in the latter it was stated that this was only for those tinnitus patients with severe hearing loss. ¹⁴ In three guidelines cochlear, implants were not recommended based on the risk of bias of outcomes, ¹³ lack of evidence on the effectiveness for normal hearing tinnitus patients ¹⁵ or the low quality of the found evidence. ¹⁹

[§]Guided by the CEBMC.27

[¶]Based on AAP classification for clinical practice guidelines,²⁹ updated with CEBMC.²⁷

^{**}Based on Minds manual version 2.0 (strength of evidence).30

^{††}Recommendation grading in the program for national health care guidelines (German Medial Association et al, 2017).

AAP, American academy of Pediatrics; CEBMC, Oxford Center of Evidence-Based Medicine criteria; GRADE, Grading Recommendations Assessment, Development and Evaluation; RCT, randomised controlled trial; SR, systematic review.

| Guideline, year | Aimed study design to be included studies | Design of included studies (when reported) | Electronic literature database searched | Search date |
|--------------------------------|---|---|--|-------------------------|
| Sweden 2011 ²¹ | | | | |
| Tinnitus severity | NR | NR | NR - | NR |
| QoL-Tinnitus specific | | NR | | |
| QoL general | | NR | | |
| Harm/risks | | NR | | |
| USA 2014 ¹⁶ | | | | |
| Tinnitus severity | SR and RCTs* | SR, Cochrane review, case- control, prospective study | Medline, EMBASE, CINAHL, Cochrane, NICE, country- specific databases | Till 2008–2013 |
| QoL-Tinnitus specific | | Cochrane review, AHRQ CER | | |
| QoL general | | NR | | |
| Harm/risks | | Meta-analysis | | |
| Germany 2015 ¹⁵ | | | | |
| Tinnitus severity | When available SR and RCTs were used | Meta-analysis, Cochrane reviews, observational studies, RCTs, single-arm studies. | Pubmed, Cochrane | 1980–2014† |
| QoL-Tinnitus specific | | NR | | |
| QoL general | | NR | | |
| Harm/risks | | Cochrane review, single-arm trail | | |
| NL 2016 ¹³ | | | | |
| Tinnitus severity | The guideline authors preselected treatments of which an SR or MA existed | SR, RCT | Medline, EMBASE, Cochrane | 1979–2016 |
| QoL-Tinnitus specific | | Meta-analysis | | |
| QoL general | WINCH AIT ON OF WIA EXISTED | Meta-analysis | | |
| Harm/risks | | RCT | | |
| Denmark 2017 ¹⁸ | | | | |
| Tinnitus severity | NR | NR | NR | NR |
| QoL-Tinnitus specific | | NR | | |
| QoL general | | NR | | |
| Harm/risks | | NR | | |
| Switzerland 2019 ²² | | | | |
| Tinnitus severity | NR | NR | NR | NR |
| QoL-Tinnitus specific | | NR | | |
| QoL general | | NR | | |
| Harm/risks | | NR | | |
| Europe 2019 ¹⁹ | | | | |
| Tinnitus severity | The guideline authors made their recommendations based | SR, RCT, scoping review, meta- analysis | Medline, Pubmed, CINAHL, guideline.gov, NICE, GIN, | Till 05–2016 |
| QoL-Tinnitus specific | on existing tinnitus guidelines | RCT | google. | |
| QoL general | | NR | | |
| Harm/risks | | RCT, clinical trails | | |
| Japan 2020 ¹⁷ | | | | |
| Tinnitus severity | SR, meta-analysis, RCTs | SR, RCTs, Guideline | Cochrane, Medical Journal web, PubMed | 1980–31 December 201 |
| QoL-Tinnitus specific | | NR | | |
| QoL general | | NR | | |
| Harm/risks | | NR | | |
| UK 2020 ²⁰ | | | | |

Continued



Table 3 Continued

| Guideline, year | Aimed study design to be included studies | Design of included studies (when reported) | Electronic literature database searched | Search date |
|----------------------------|--|---|---|-----------------------|
| Tinnitus severity | RCTs. If there is an inadequate amount of RCT data, non- | RCTs, Cochrane review | Medline, EMBASE, Cochrane, CINAHL | Till 2004–2019 |
| QoL-Tinnitus specific | | RCTs, Cochrane review | | |
| QoL general | | RCTs, Cochrane review | | |
| Harm/risks | considered. | RCTs, Cochrane review | | |
| Germany 2021 ¹⁴ | | | | |
| Tinnitus severity | SR, RCT, observational studies | SR, RCTs, case–control studies, feasibility study | PubMed, Cochrane | 01–2014 to 12–2020 |
| QoL-Tinnitus specific | | Cohort study, randomised trial | | |
| QoL general | | NR | | |
| Harm/risks | | RCTs | | |

*SR and RCTs. (Where data were lacking, a combination of clinical experience and expert consensus was used). †Search data depended per subject. (1980–2014 widest search range).

AHRQ CER, Agency for Healthcare Research and Quality Comparative effectiveness Research; CINAHL, Cumulative Index to Nursing and Allied Health Literature; EMBASE, Excerpta Medica Database; HUI, Health Utilities Index; NICE, National Institute for Health and Care Excellence; NR, not reported; QoL, quality of life; RCT, randomised controlled trial; SR, systematic review.

Other treatments

Acupuncture (6 out of 10 guidelines), ¹³⁻¹⁷ ¹⁹ dietary supplements (4 out of 10 guidelines), ¹³ ¹⁵ ¹⁶ ¹⁹ drug therapy (7 out of 10 guidelines), ¹³⁻¹⁷ ¹⁹ ²⁰ acoustic CR neuromodulation (4 out of 10 guidelines), ¹³ ¹⁵ ¹⁹ ²⁰ rTMS (7 out of 10 guidelines), ¹³⁻¹⁷ ¹⁹ ²⁰ TDCS (5 out of 10) ¹³⁻¹⁵ ¹⁹ and NVS (3 out of 10 guidelines) ¹⁴ ¹⁹ ²⁰ were consistently not recommended by any guideline, with minimal differences in level of recommendation.

DISCUSSION

In this SR of the literature, we compared the design, development and recommendations in guidelines on treatment options for chronic tinnitus in adults. A total of 10 guidelines were identified and included, published between 2011 and 2021. Recommendations for 13 types of tinnitus treatments were compared. Counselling and CBT were the only treatments which were recommended for treating tinnitus by all guidelines that reported on these topics. Other treatment options were not unanimously recommended, either due to the lack of evidence, a high risk of bias or judgement of no beneficial effect of the specific treatment.

Within our study, we found that recommendations between guidelines varied more when the quality and quantity of the evidence was low, which is in line with guideline comparisons in other fields. Some of the included guidelines gave no recommendation when the level of evidence was judged as too low, whereas other guidelines gave a recommendation against the treatment or stated that the treatment was 'optional' on the same basis. This could explain the found differences in recommendations and the stated level of recommendation for TRT, CI and sound therapy. Due to poor reporting the rationale behind these choices was not always clear. One should keep in mind that there is a difference between 'no

recommendation' and 'recommendation against'. 'No recommendation' can be reported by a guideline due to the lack of evidence. A recommendation against a treatment option can be given because of a lack of evidence, but also because the evidence points out that a treatment does not work. Differences in recommendations between guidelines could also be explained by the fact that newer guidelines relied on more recent evidence for the specific topic. For example; in the updated German guideline of 2021, 14 recommendations against rTMS and TDCS were made, while in the original German guideline of 2015¹⁵ an uncertain recommendation was provided for these treatments. Also, TRT was not recommended in the original German guideline, whereas in the updated guideline an open recommendation was given for the long-term outcome effects. 14 15

Ideally, recommendations in clinical guidelines are based on SRs of the available evidence. If those are not yet available at the time of writing of the guideline, guideline developers should conduct a SR themselves. In 7 out of 10 included guidelines in our study a SR of literature was performed as part of the guideline development 13-17 19 20 and in 3 guidelines the source on which they based their recommendations on was not reported. 18 21 22 Out of those seven guidelines in which a SR was described, the Dutch guideline¹³ only selected treatment types for their recommendations for which an SR or MA already existed. Besides this, the European guideline¹⁹ based its recommendations on outcomes of existing guidelines. However, a systematic assessment of the available evidence on topics is essential for the development of a guideline.⁹ Only by this, the potential of current and new therapies and their evidence can be assessed in terms of possible benefits as well as harms and alternative care options to be able to provide the patient with the best advice.³ Unfortunately, it has been found that over half of clinical

practice guidelines do not base their evidence synthesis in SRs which results in misleading and untrustworthy recommendations.³¹

A rigid SR of the literature can yield high quality, trustworthy evidence, very low quality evidence or something in between. It is essential for clinicians to be informed about the quality of evidence on which recommendations are made. Therefore, appraisal of the evidence is an important step in the development of a guideline. 32 This is especially true for the field of tinnitus treatment, where high-quality RCTs are scarce. Most guidelines that were included in our study used either GRADE method²⁸ or CEBMC²⁷ as framework for this appraisal. However, some guidelines applied these tools in different ways then was intended by the creators of the frameworks. For example, GRADE was used in the EU guideline to classify the level of recommendation instead of the level of evidence. Other guidelines applied their own adapted version of commonly used methods or combined two different frameworks. 14 16 This makes comparison of the provided levels of evidence or levels of recommendation between the guidelines difficult, if not impossible, and complicates the judgement of the reader on this. Beside the adequate use of appraisal tools, also a predefined definition of the outcome measure to rely the recommendation on is essential to find the best available evidence. Remarkably, only 1 out of 10 guidelines included harms of treatment as a predefined outcome measure.¹³ Three other guidelines did also report this outcome in their final evidence synthesis but were inconsistent in their reporting. 14 16 19 This needs attention in future guidelines to help physicians and patients in their decision-making. Performing a SR of available evidence takes time and we need to consider that developing and publishing a (national) guideline is a costly process. One could argue if, in times of rapid medical advancements in a field, recommendations are still up to date at the time of final publication. Also as discussed in Langguth *et al*, the current methods for guideline development can cause a delay of up to 10+ years before a new treatment option is recommended by a guideline. A more dynamic, digital and open access (international) guideline could be of value to solve this limitation and needs to be considered for the next future.

Besides appraisal of the evidence, clear reporting in guidelines is essential to create a trustworthy outcome. The EQUATOR network, a network that specialises in writing reporting guidelines for biomedical research, recommends using the AGREE or RIGHT statements or checklists to reach high-quality reporting. ^{12 33} However, using a guideline checklist does not imply that the guideline is of sufficient quality. ³⁴ The Swedish, Swiss and Danish guidelines did not report the use of a reporting tool. ^{18 21 22} While this does not necessarily mean they did not use it, these guidelines lacked transparency and clear reporting. This lack of adequate reporting is not unique for tinnitus research and guidelines. Previously, reporting quality in guidelines of specialty societies was found to be generally of low quality. ³⁵ Adherence to reporting

guidelines should be advocated to ensure the provided statements in a guideline are trustworthy, reproducible and applicable for the stated patient and setting.

In line with the low level of reporting, reporting on possible conflicts of interest, funding and group membership was lacking in several guidelines. 16-18 21 Also interests of involved patient associations, the medical industry and specialty societies were sometimes unclear and only in a minority of the guidelines it was stated if different opinions existed on the recommendations to be made and how this was handled. 14 Conflicts of interest can be financial but can also arise from a personal, political, academic or professional role.36 Financial conflict of interest is a known problem in guideline development but remains largely hidden. 37 38 These conflicts of interest may cause bias in the given recommendations and can ultimately be harmful to patients and the healthcare system. 39 40 For this reason, editorial independence and transparency is important and should be promoted and pursued. ³⁶ ³⁷ ⁴¹ Integration of the expertise of all involved specialties is essential in the development of clinical guidelines. In tinnitus guidelines, multiple different clinical specialties were involved, but none reported collaboration of an epidemiologist or methodologist. This while these competencies are crucial for evaluating the evidence.42

The measures of effectiveness that were used in clinical practice guidelines could also hinder applicability. In most guidelines, outcomes on effectiveness of treatments were expressed in terms of tinnitus severity, tinnitus-related quality of life or general quality of life. However, it is debatable if these outcomes are the most important for tinnitus patients. As described in previous studies, tinnitus patients mostly seek reduction of tinnitus loudness and elimination of their tinnitus in treatment, whereas healthcare workers such as audiologists described that a decreased awareness and anxiety relief would be the most important to determine treatment success. 43 44 These differences in expectations of tinnitus treatment could hinder the applicability of outcomes of tinnitus guidelines made by experts for patients, which is also noticed in other fields of research.⁴⁵ Therefore, integrating patient and patient representatives in future guideline development is of utmost importance. To provide patients and patient representatives even better information one could also consider to publish a shortened patient focused guideline together with the newly developed guideline.

One could debate if all included guidelines in our study can be considered as clinical practice guidelines by the lack of a systematic assessment or reporting of this assessment in several of those, ¹³ ¹⁸ ¹⁹ ²¹ ²² and to be compared with the other (evidence based) published tinnitus guidelines in the current study. Also, in this study, we included clinical guidelines without a publication date restriction. This choice on inclusion of guidelines and publication date was made because even when guidelines are maybe 'outdated', or do not adhere to formal definitions of



guidelines, they are sometimes still in use in the country in which they were published and findable for patients and healthcare workers on websites. We used predefined inclusion and exclusion criteria and used the PRISMA reporting guideline for SRs of literature and the AGREE checklist to investigate the reporting of the included guidelines. 11 12 We chose to use the AGREE checklist to report on reporting of the guidelines instead of the AGREE-II tool. 12 The AGREE checklist does not require the researcher to determine a score for each domain, which makes it less dependent on the opinion of the researchers. Besides these strengths, there is a limitation to our study that has to be taken into account. The lack of a published research protocol for this study could in theory cause publication bias and makes it impossible for the readership to check our predefined study outcomes.

Future tinnitus guideline development could profit from the use of specialised reporting tools (like AGREE¹² or RIGHT³³) to improve reporting and transparency and the help of guideline development specialists. Second, it is questionable if it is feasible and advisable to develop new and update existing national guidelines on a topic for countries that have similar healthcare settings. Additionally, tinnitus patients and specialists in guideline development should be more involved in future guideline development to optimise the investigated outcomes of research.

Contributors ALS and IS designed and planned the study. SM, JAvdL, SAA, ALS and IS were involved in the literature search and selection of the evidence. SM wrote the draft. JAvdL, SAA and SM designed the evidence tables. SM, JAvdL, SAA, ALS and IS contributed to the interpretation of the results. ALS and IS revised the manuscript and supervised SM. SM is the guarantor of this study. All authors approved the final version of this study.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval No ethics approval was required for this systematic review of literature.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All useful data are published within the article itself (and supplementary files). The Excel file is available on request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Sebastiaan Meijers http://orcid.org/0000-0001-5991-696X Inge Stegeman http://orcid.org/0000-0001-5154-7178

REFERENCES

- 1 Langguth B, Kleinjung T, Schlee W, et al. Tinnitus guidelines and their evidence base. J Clin Med 2023:12:3087.
- 2 Cima RFF, Kikidis D, Mazurek B, et al. Tinnitus healthcare: a survey revealing extensive variation in opinion and practices across Europe. BMJ Open 2020;10:e029346.
- 3 Graham R, Mancher M, Wolman DM, eds. *Clinical practice guidelines we can trust*. Washington, D.C, 2011.
- 4 Masic I, Miokovic M, Muhamedagic B. Evidence based medicinenew approaches and challenges. Acta Inform Med 2008;16:219.
- 5 Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71–2.
- 6 Burgers JS, Bailey JV, Klazinga NS, et al. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. *Diabetes Care* 2002;25:1933–9.
- 7 Piso B, Reinsperger I, Winkler R. Recommendations from international clinical guidelines for routine antenatal infection screening: does evidence matter *Int J Evid Based Healthc* 2014;12:50–61.
- 8 Wilson MC, Hayward RS, Tunis SR, et al. Users' guides to the medical literature. VIII. how to use clinical practice guidelines. B. what are the recommendations and will they help you in caring for your patients? the evidence-based medicine working group. JAMA 1995;274:1630–2.
- Djulbegovic B, Guyatt G. Evidence vs consensus in clinical practice guidelines. *JAMA* 2019;322:725–6.
- 10 Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan---a web and mobile app for systematic reviews. Syst Rev 2016;5:210.
- 11 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021:372:n71.
- 12 Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. BMJ 2016;352:i1152.
- 13 Dutch Association for ear nose throat and head and neck surgery (NEDERLANDSE Vereniging Voor Keel- Neus- Oorheelkunde en Heelkunde Van Het Hoofdhals Gebied). Tinnitus guideline (Richtlijn Tinnitus) 2016
- Mazurek B, Hesse G, Sattel H, et al. S3 guideline: chronic Tinnitus: German society for otorhinolaryngology, head and neck surgery E. V. (DGHNO-KHC). HNO 2022;70:795–827.
- 15 The Association of the scientific Medical Societies (AWMF). German S3 Guideline: 017/064: Chronic tinnitus. 2015;(017/064 S3).
- 16 Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. Otolaryngol--Head Neck Surg 2014;151.
- 17 Ogawa K, Sato H, Takahashi M, et al. Clinical practice guidelines for diagnosis and treatment of chronic tinnitus in Japan. Auris Nasus Larynx 2020;47:1–6.
- 18 Danske Tale-Hore-Synsinstitutioner (DTHS. Guidance for Diagnosing Tinnitus and Hyperacusis (Vejledning for udredning af tinnitus og hyperakusis). 2017.
- 19 Cima RFF, Mazurek B, Haider H, et al. A Multidisciplinary European guideline for tinnitus: diagnostics, assessment, and treatment. HNO 2019;67(Suppl 1):10–42.
- 20 National Institute of Health and Care Excellence (NICE). Tinnitus: assessment and managment. London, 2020.
- 21 Karolinska Institute. Tinnitus care program (Tinnitus Vardprogram). Stockholm, 2011.
- 22 Stanimirow O, Huber F. Guideline Tinnitus. 2019.
- 23 Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the conference on guideline standardization. *Ann Intern Med* 2003;139:493–8.
- 24 Rosenfeld RM, Shiffman RN. Clinical practice guideline development manual: a quality-driven approach for translating evidence into action. Otolaryngol Head Neck Surg 2009;140(6 Suppl 1):S1–43.
- 25 The Association of the scientific Medical Societies (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI).
- 26 Adviescommissie Richtlijnen Raad Kwaliteit. Medisch Specialistische Richtlijnen 2.0. 2011.
- 27 Howick J, Chalmers I, Glasziou P, et al. The Oxford 2011 levels of evidence. Oxford Centre Evidence-Based Medicine Group 2011;1:5653.



- 28 Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
- 29 American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. *Pediatrics* 2004;114:874–7.
- 30 Kojimahara N, Nakayama T, Morizane T, et al. Minds manual for guideline development 2017. Tokyo Japan Counc Qual Heal Care 2017.
- 31 Lunny C, Ramasubbu C, Puil L, et al. Over half of clinical practice guidelines use non-systematic methods to inform recommendations: a methods study. PLoS One 2021;16:e0250356.
- 32 Brignardello-Petersen R, Carrasco-Labra A, Guyatt GH. How to interpret and use a clinical practice guideline or recommendation: users' guides to the medical literature. *JAMA* 2021;326:1516–23.
- 33 Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med 2017;166:128–32.
- 34 Logullo P, MacCarthy A, Kirtley S, et al. Reporting guideline checklists are not quality evaluation forms: they are guidance for writing. Health Sci Rep 2020;3. 10.1002/hsr2.165 Available: https:// onlinelibrary.wiley.com/toc/23988835/3/2
- 35 Grilli R, Magrini N, Penna A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000;355:103–6.
- 36 Traversy G, Barnieh L, Akl EA, et al. Managing conflicts of interest in the development of health guidelines. CMAJ 2021;193:E49–54.

- 37 Moore A, Straus S, Lexchin J, et al. Financial conflict of interest among clinical practice guideline-producing organisations. *Br J Gen Pract* 2020;70:530–1.
- 38 Bindslev JBB, Schroll J, Gøtzsche PC, et al. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Med Ethics 2013;14:19.
- 39 Norris SL, Holmer HK, Ogden LA, et al. Conflict of interest in clinical practice guideline development: a systematic review. PLoS One 2011:6:e25153.
- 40 Nejstgaard CH, Bero L, Hróbjartsson A, et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ 2020;371:m4234.
- 41 Cosgrove L, Shaughnessy AF, Shaneyfelt T. When is a guideline not a guideline? the devil is in the details. *BMJ Evid Based Med* 2018:23:33–6.
- 42 Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ 1999;318:593–6.
- 43 McFerran DJ, Stockdale D, Holme R, et al. Why is there no cure for tinnitus? Front Neurosci 2019;13:802.
- 44 Husain FT, Gander PE, Jansen JN, *et al.* Expectations for tinnitus treatment and outcomes: a survey study of audiologists and patients. *J Am Acad Audiol* 2018;29:313–36.
- 45 Armstrong MJ, Mullins CD, Gronseth GS, et al. Impact of patient involvement on clinical practice guideline development: a parallel group study. Implement Sci 2018;13:55.